Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.46 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5903491 | 0.94 | MAPK14 (0.68) | MAPK14MAP4K4CSNK1DMAPK9CSNK1A1 | |
| SCHEMBL7162537 | 0.93 | MAPK14 (0.67) | MAPK14MAP4K4CSNK1DMAPK9CSNK1A1 | |
| SCHEMBL4347807 | 0.87 | MAPK14 (0.68) | MAPK14MAP4K4CSNK1DMAPK9CSNK1A1 | |
| SCHEMBL27489999 | 0.85 | MAPK14 (0.58) | MAPK14MAPK10MAPK11MAPK13MAPK12 | |
| SCHEMBL6587012 | 0.84 | MAPK14 (0.66) | MAPK14MAPK10MAPK11MAPK13MAPK12 | |
| SCHEMBL5858720 | 0.84 | MAPK14 (0.66) | MAPK14MAPK10MAPK11MAPK13MAPK12 | |
| SCHEMBL7139249 | 0.84 | MAPK14 (0.66) | MAPK14MAP4K4CSNK1DMAPK9CSNK1A1 | |
| SCHEMBL6581107 | 0.84 | MAPK14 (0.66) | MAPK14MAPK10MAPK11MAPK13MAPK12 | |
| SCHEMBL1127766 | 0.84 | MAPK14 (0.66) | MAPK14MAPK10MAPK11MAPK13MAPK12 | |
| SCHEMBL1127850 | 0.83 | MAPK14 (0.62) | MAPK14MAP4K4MAPK10MAPK11MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289511-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2009132068-A2 | TREATMENT OF PLURIPOTENT CELLS | CENTOCOR ORTHO BIOTECH INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009017795-A1 | INDAZOLE COMPOUNDS FOR TREATING INFLAMMATORY DISORDERS, DEMYELINATING DISORDERS AND CANCERS | XANTHUS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | XANTHUS PHARMACEUTICALS, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | PMP22, PML, AQP4 | MAPK14 1192/4885MAP4K4 1754/4885CSNK1D 2871/4885 |
| US-20120289511-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | MAPK14 4676/4885MAP4K4 4048/4885CSNK1D 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.